Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.35 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15662428 | 0.85 | MAPK1 (0.35) | RORC | |
| SCHEMBL3407549 | 0.82 | MAPK1 (0.36) | RORC | |
| SCHEMBL3152349 | 0.81 | CHEK2 (0.39) | BTKTP53 | |
| SCHEMBL3138154 | 0.81 | RORC (0.36) | RORCMAPTTP53 | |
| SCHEMBL4221224 | 0.81 | RORC (0.36) | RORCMAPTTP53 | |
| SCHEMBL15662904 | 0.75 | RORC (0.32) | RORC | |
| SCHEMBL15662420 | 0.75 | MAPT (0.37) | MAPT | |
| SCHEMBL4222585 | 0.74 | MAPK1 (0.39) | — | |
| SCHEMBL15661778 | 0.73 | PKN1 (0.36) | — | |
| SCHEMBL15661362 | 0.72 | PIK3CA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2155722-B1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2155722-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | PARP10 949/4885RORC 2751/4885GLA 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.